Sanofi S.A. – Company Overview
|Headquarters||54, Rue La Boétie, 75008 Paris, France|
|Founder||Jean-François Dehecq and Jean-René Sautier|
|NYSE stock symbol||SNY|
|Net Sales||€34,542 million EUR (2015)|
|Operating income||€5,624 million EUR (2015)|
|Net income||€4,388 million EUR (2015)|
|IR contact number||+33 (0)1 53 77 40 00|
|IR email address||[email protected]|
Sanofi S.A. focuses on the development and production of prescription drugs, over-the-counter drugs, and vaccines. Some of its most notable products are:
- Zolpidem (Ambien) – an anxiolytic sedative
- Glimepiride (Amaryl) – a sulfonylureas drug for type 2 diabetes mellitus
- Enoxaparin (Lovenox) – drug for thrombosis
- Insulin (Lantus) – drug for diabetes
In 1973 Sanofi was created as a subsidiary of Elf Aquitaine (French oil company) following its acquisition of the pharmaceutical company Labaz.
In 1999 Sanofi merged with a former subsidiary of L’Oréal called Synthélabo, to create Sanofi-Synthélabo.
In 2004 Sanofi-Synthélabo merged with Aventis and changed its name to Sanofi-Aventis.
However, in 2011 the company decided to remove the -Aventis suffix. Partly because Sanofi (on its own) is easier to pronounce in countries such as China.
Sanofi has acquired the following companies since 2009:
- Medley (A Brazilian pharmaceutical company)
- Chattem, Inc.
- BMP Sunstone Corporation
- Genzyme Corporation (a biotechnology group)
Sanofi is the result of several mergers and acquisitions.
Sanofi S.A. – Financial Results
|Key figures (in millions of EUR)||2015*||2014*|
|Cash and cash equivalents at beginning of period||€7,341||€8,257|
|Cash and cash equivalents at end of period||€9148||$7,341|
*For the years ended December 31, 2015 and 2014
Source: “Sanofi S.A. – 2015 Form 20-F”